Evidence map›Paper›PMID 38865586›Full record

ReviewThe FEBS journal2025

Less is better: various means to reduce protein load in the endoplasmic reticulum.

Salam Dabsan, Gal Twito, Suma Biadsy, Aeid Igbaria

Abstract readReview
In one paragraph

Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Spatial protein redistribution: wandering but not lost.Cellular and molecular life sciences : CMLS · 2025
    Review
  11. Review
  12. Glycosylation Regulation by TMEM230 in Aging and Autoimmunity.International journal of molecular sciences · 2025
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Salam DabsanDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Gal TwitoDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Suma BiadsyDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Aeid IgbariaDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.ORCID 0000-0003-3940-1824

Funding

Israel Cancer Research Fund 23-202-RCDAIsrael Science Foundation 977/21
6 · The paper itself

Abstract

The endoplasmic reticulum (ER) is an important organelle that controls the intracellular and extracellular environments. The ER is responsible for folding almost one-third of the total protein population in the eukaryotic cell. Disruption of ER-protein folding is associated with numerous human diseases, including metabolic disorders, neurodegenerative diseases, and cancer. During ER perturbations, the cells deploy various mechanisms to increase the ER-folding capacity and reduce ER-protein load by minimizing the number of substrates entering the ER to regain homeostasis. These mechanisms include signaling pathways, degradation mechanisms, and other processes that mediate the reflux of ER content to the cytosol. In this review, we will discuss the recent discoveries of five different ER quality control mechanisms, including the unfolded protein response (UPR), ER-associated-degradation (ERAD), pre-emptive quality control, ER-phagy and ER to cytosol signaling (ERCYS). We will discuss the roles of these processes in decreasing ER-protein load and inter-mechanism crosstalk.

Indexed as

Endoplasmic ReticulumAnimalsCytosolEndoplasmic Reticulum-Associated DegradationHumansProtein FoldingSignal TransductionUnfolded Protein ResponseCOPIIERADERCYSER‐PhagyER‐pQCUPR

Identifiers

PMID38865586
PMCPMC11880973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.